Roche announced positive results from the evERA Breast Cancer study, showing giredestrant plus everolimus reduced disease progression risk by 44% and 62% in ITT and ESR1-mutated populations post-CDK inhibitor treatment. The combination was well tolerated with no new safety signals. If approved, it could be the first oral selective oestrogen receptor degrader in this setting. Results were presented at the European Society for Medical Oncology Congress 2025, supporting giredestrant as a potential new standard-of-care for resistant patients. The combination showed significant improvement in PFS and secondary endpoints, with manageable adverse events. The study continues to evaluate overall survival data and will be shared with health authorities. The combination of giredestrant plus everolimus showed significant reductions in disease progression or death in patients with ER-positive breast cancer after CDK inhibitor treatment. The giredestrant combination demonstrated good tolerability with no new safety concerns. Overall survival data is promising, with a positive trend observed in both ITT and ESR1-mutated populations. If approved, this could be the first oral selective estrogen receptor degrader combination in this setting. Giredestrant is part of a comprehensive clinical development program, investigating its efficacy in various treatment settings for breast cancer. ER-positive breast cancer accounts for 70% of cases, presenting treatment challenges due to its biological complexity. Roche is dedicated to advancing breast cancer research and providing tailored treatment approaches to improve patient outcomes. Giredestrant plus everolimus demonstrated a significant reduction in disease progression or death risk in post-CDK inhibitor settings. The combination was well-tolerated with no new safety signals observed. Overall survival data showed a positive trend in both populations. If approved, it could be the first oral selective oestrogen receptor degrader combination in this setting. These findings were presented at the European Society for Medical Oncology Annual Meeting. Further studies are ongoing to evaluate the efficacy and safety of giredestrant in various breast cancer settings. For more information, refer to the provided links.

Read more at Giredestrant plus everolimus shows promising results in reducing disease progression or death in post-CDK inhibitor setting. Overall survival data still pending. No new safety concerns observed. Potential approval as first oral selective estrogen receptor degrader combination in this setting. (GlobeNewswire): Roche’s phase III evERA data showed giredestrant